MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Blepharospasm"

  • MDS Virtual Congress 2021

    Blepharospasm – a network disorder

    MC. Posirca, R. Ivan, I. Caloianu, M. Mitrica, CA. Sirbu (Bucharest, Romania)

    Objective: We present a case with apraxia of eyelid opening,  orbicularis oculi spasms, increased blinking, which falls within the new paradigm that defines blepharospasm, that…
  • MDS Virtual Congress 2021

    The main reasons for essential blepharospasm botulinum neurotoxin (BoNT) treatment discontinuation in Latvian population.

    K. Lazdovska, R. Valante (Riga, Latvia)

    Objective: To investigate the effectiveness of BoNT treatment in patients with essential blepharospasm and determine the most common reasons for discontinuation of the treatment. Background: Essential…
  • MDS Virtual Congress 2021

    Does Microneedle Use for Facial Injection of Botulinum Toxin Reduce Pain? A Systematic Literature Review

    S. Maytharakcheep (Bangkok, Thailand)

    Objective: To perform a systematic review to identify relevant literature on pain outcomes after injecting BTX with a microneedle for various facial conditions and to…
  • MDS Virtual Congress 2021

    Gait Dysfunction in Blepharospasm

    H. Sarva, S. Lons, T. Baumer, C. Klein, H. Jinnah (New York, USA)

    Objective: Characterizing gait in blepharospasm patients. Background: Blepharospasm ranges from frequent blinking to forced eye closure potentially causing functional blindness that can impair walking. Gait…
  • MDS Virtual Congress 2020

    Long-term safety and efficacy of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects: results of a Phase III study

    F. Pagan, A. Dekundy, M. Althaus, D. Mitsikostas (Washington, DC, USA)

    Objective: To assess the safety and efficacy of incobotulinumtoxinA for benign essential blepharospasm (BEB) in toxin-naïve subjects. Background: IncobotulinumtoxinA is efficacious for BEB. This was…
  • MDS Virtual Congress 2020

    Duration of Effect of IncobotulinumtoxinA for the Treatment of Blepharospasm in Botulinum Toxin-naïve Subjects: Results from a Phase III Study

    F. Pagan, A. Dekundy, M. Althaus, A. Scheschonka, J. Jankovic, D. Mitsikostas (Washington, DC, USA)

    Objective: The efficacy of incobotulinumtoxinA, a botulinum neurotoxin type A free from complexing proteins, was investigated in a randomized, placebo-controlled, prospective, Phase III study in…
  • MDS Virtual Congress 2020

    FL-41 Lenses for the Treatment of Meige Syndrome

    A. Vickers, A. Lee, T. Campbell (Las Vegas, NV, USA)

    Objective: A case report demonstrating successful treatment of Meige syndrome with FL-41 rose-tinted lenses. Background: Meige syndrome is a rare disorder characterized by blepharospasm and…
  • MDS Virtual Congress 2020

    Smell and Taste in Blepharospasm

    J. Gamain, T. Herr, T. Hummel, B. Veit, C. Willert, B. Lehnert, R. Fleischmann, A. Stenner, F. Tost, M. Kronenbürger (Greifswald, Germany)

    Objective: To contribute to the better understanding of blepharospasm, we systematically assess olfactory and gustatory ability in subjects with blepharospasm, compared to subjects with cervical…
  • MDS Virtual Congress 2020

    Cost-Utility Analysis of Flexible Intervals with IncobotulinumtoxinA Versus Fixed Dosing with OnabotulinumtoxinA in the Management of Cervical Dystonia and Blepharospasm in Major Canadian Markets

    M.E Gendron, R. Kazerooni, D. Vézina (Burlington, ON, Canada)

    Objective: The aim was to carry out a cost-utility analysis for IncobotulinumtoxinA (INCO) administered with flexible treatment intervals compared to onabotulinumtoxinA (ONA) administered with fixed…
  • 2019 International Congress

    Depression and cognitive impairment in isolated focal-onset dystonia: prevalence and risk factors in a group of Romanian patients

    OL. Bajenaru, I. Popescu-Olaru, E. Serban, L. Cozma, F. Raicu, R. Cocos, L. Dumitrescu, BO. Popescu (Bucharest, Romania)

    Objective: To assess the prevalence of depression and cognitive impairment and their potential risk factors in a group of Romanian patients with isolated focal-onset dystonia…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley